SCI Abstract

search
+
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
What is this summary about? This is a summary of the results of a study called PHAROS. This study looked at combination tr...
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Interactions between tumor cells and immune cells in the tumor microenvironment (TME) play a vital role the mechanisms of ...
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA
Aim: Real-world treatment patterns in tenosynovial giant cell tumor (TGCT) patients remain unknown. Pexidartinib is the on...
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT
What is this summary about? This summary describes a publication about a study called SPRINT. The SPRINT study included 50...
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
What is this summary about? In this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study pu...
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma
Elranatamab efficacy in the single-arm, registrational MagnetisMM-3 trial (NCT04649359) was compared with that of physicia...
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)
An observational study of once-weekly carfilzomib in patients with multiple myeloma in Japan (Weekly-CAR study)
Background: The ARROW study demonstrated that once-weekly carfilzomib and dexamethasone (wKd) therapy significantly prolon...
Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors
Design of a single-center, phase II trial to explore the efficacy and safety of ‘R-ISV-RO’ treatment in advanced tumors
Background: The authors' preclinical study has confirmed that RO adjuvant (composed of TLR 7 agonists [imiquimod/R837] and...
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
Progression-free survival and safety at 3.5 years of follow-up: results from the randomized phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer – a plain language summary
What is this summary about? This PLSP provides a short summary of an original scientific article that presented results fr...
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study
Prolonging the lives of African–Americans with metastatic breast cancer by adding palbociclib to an aromatase inhibitor in routine clinical practice: a plain language summary of a real-world database study
This summary is about a study that was published in the medical journal The Oncologist in July 2023. The combination of pa...
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary
Treatment outcomes in older patients with metastatic breast cancer receiving palbociclib plus an aromatase inhibitor: a plain language summary
What is this summary about? This summary describes an article published in the medical journal Frontiers in Oncology in Se...
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen
What is this summary about? People diagnosed with a disease called large B-cell lymphoma (LBCL) may experience return, or ...
Patient engagement in designing and publishing research in prostate cancer: a scoping review
Patient engagement in designing and publishing research in prostate cancer: a scoping review
Patients with cancer have the unique ability of being able to offer valuable insights into how cancer therapeutics may imp...
Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer
Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer
Aim: To evaluate a novel antisense oligonucleotide drug targeting human IGF-1R in preclinical and phase I studies of liver...
Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries
Real-world evidence in the reassessment of oncology therapies: payer perceptions from five countries
Aim: This study explored the perceived value of real-world evidence (RWE) in the reassessment of oncology therapies by col...
The impact of myelosuppression on quality of life of patients treated with chemotherapy
The impact of myelosuppression on quality of life of patients treated with chemotherapy
Side effects from chemotherapy-induced myelosuppression can negatively affect patients' quality of life (QoL). Neutropenia...
Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study
Immunotherapy combined with cranial radiotherapy for driver-negative non-small-cell lung cancer brain metastases: a retrospective study
Background: This study assesses immune checkpoint inhibitors’ efficacy for non-small-cell lung cancer (NSCLC) with brain m...
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Study design for DESTINY-Breast Respond HER2-low Europe: T-DXd in patients with HER2-low advanced breast cancer
Trastuzumab deruxtecan (T-DXd) is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-low metast...
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer
Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer
Aim: A systematic review and network meta-analysis (NMA) was performed to evaluate the efficacy of first-line treatments f...
Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan
Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan
Aim: Cost–effectiveness analysis (CEA) was performed to compare axicabtagene ciloleucel (axi-cel) with tisagenlecleucel (t...
format_indent_increase